In the current session, Evofem Biosciences Inc. (NASDAQ:EVFM) is trading at $6.04, after a 21% increase. Over the past month, the stock increased by 25.57%, and in the past year, by 2.03%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently down from its 52 week high by 19.47%.

Depending on the particular phase of a business cycle, some industries will perform better than others.

Compared to the aggregate P/E ratio of 0.0 in the biotechnology industry, Evofem Biosciences has a higher P/E ratio of 0.0. Shareholders might be inclined to think that Evofem Biosciences might perform better than its industry group. It’s also possible that the stock is overvalued.

P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.